Hims & Hers Health, Inc.(HIMS)NASDAQ
Stock Overview & Analysis
Hims & Hers Health, Inc. (HIMS) quick overview 2026-02-20
- The stock is currently trading at $15.63, experiencing a short-term pullback within a declining trend—trading below its 50-day average while below the 200-day.
- Analysts appear optimistic, with a 1-year price target of $29.96 (91.7% upside).
- Volatility is elevated (68.47% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (49.20% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.09B
P/E Ratio
Forward P/E: 14.86
Revenue Growth
Year over Year
Analyst Target
+91.7% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Oversold (RSI 12.84)
- Fundamentals say: Caution warranted (high leverage concerns)
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $1.12B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
Trading Range
Over the past year, the stock traded between $15.46 and $72.98—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 68.47% annualized volatility and β=2.47, the stock exhibits high sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for.
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside
HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.
Nvidia Earnings, PPI: What to Watch Next Week
Investors next week will focus on a quarterly update from Nvidia, whose results have become a bellwether for the broader artificial-intelligence trade. They also will assess the health of the American consumer through confidence data and earnings from home-improvement retailers Home Depot and Lowe’s.
Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?
Hims & Hers Health (NYSE:HIMS) just made a bold move to take its personalized wellness platform global. The company announced it is acquiring Eucalyptus, a leading digital health player based in Australia, in a deal worth up to $1.15 billion. The move aims to accelerate global expansion by entering Australia and Japan while strengthening its ... Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?
Hims & Hers Accelerates AI Preventive Care and Platform Strategy
HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.
Grail Stock Tanks After Cancer-Screening Study
Shares of early cancer-detection test maker Grail plunged 50% early Friday after a landmark U.K. study showed the test didn’t significantly reduce later-stage cancer cases. Grail said late Thursday that its test, called Galleri, still showed promise in the 142,000-person study with the U.
The Weekly Closeout: New Balance hits record sales in 2025, Chinese Laundry acquired
The sportswear brand brought in $9.2 billion in annual sales, while the apparel company and its sibling brands were added to Gordon Brothers’ portfolio.
Biotech Grail shares plunge after key trial fails to meet primary endpoint
Investing.com - Shares of Grail shed nearly 47% of their value in premarket U.S. trading Friday, after the biotech firm’s flagship NHS-Galleri trial failed to meet its primary clinical endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. But the California-based company reported a fourth-quarter net loss of $99.2 million, or ($2.44) per share, which significantly outperformed the consensus analyst estimate of a ($4.01) loss. Revenue for the period reac
These Stocks Are Today’s Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More
Walmart stock falls after the world’s largest retailer by revenue posts better-than-anticipated earnings.
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $15.63. The RSI (14-day) is at 12.8, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $29.96 implies 91.7% upside from current levels. Volatility is high at 68.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is 30.32, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 14.86, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.92, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 6.29. Price-to-Sales is 1.65. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $29.96. This represents a 91.7% upside from the current price of $15.63. The range spans from a low target of $13.00 to a high target of $60.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (68.5% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 192.44) which could pressure margins in a rising rate environment. 3. Elevated short interest (41.7% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.12B. The debt-to-equity ratio is 192.44, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.88, indicating strong short-term liquidity. The quick ratio is 1.49. The company holds $629.74M in cash and equivalents. Free cash flow is positive at $195.08M, providing a cushion for debt servicing and shareholder returns.